All the Company’s Resolutions Were Approved by the Shareholders Represented by Proxy at the Meeting  

Ronkonkoma, New York, USA - TheNewswire – December 15, 2022 - G6 Materials Corp. (“G6” or the “Company”) (TSXV:GGG), (OTC:GPHBF), announces the results of voting at its annual general and special meeting of shareholders which was held on December 14, 2022 (the “Meeting”).  The shareholders represented by proxy at the Meeting held 48,662,344.00 common shares, which constituted 29.73% of the Company’s total issued and outstanding common shares.  The voting results for each matter presented at the Meeting is set out below:

Number of Directors 

The resolution to set the number of directors of the Company at four (4) was approved by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting.  Voting results are set out below: 

 Election of Directors 

Each of the nominees listed for election as director in the Company’s Management Information for the year 2022, were elected as directors of G6 for the ensuing year until their successors are elected or appointed.  Voting results are set out below: 

 Appointment of Auditors 

MNP LLP, to be appointed as the auditor of the Company for the ensuing year with their remuneration to be fixed by the Board of Directors.  Voting results are set out below: 

Approval of New 10% Rolling Stock Option Plan 

The resolution to authorize and approve the new 10% rolling stock option plan of the Company was approved by a majority of votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting.  Voting results are set out below: 

About G6 Materials Corp.

G6 Materials Corp. is a high-tech company with expertise in advanced materials that creates value developing innovative composites for a wide range of industrial uses. Graphene Laboratories Inc., a wholly owned subsidiary of G6, sells a range of graphene-based products and other materials, including but not limited to conductive epoxies, high-performance composites, and R&D materials, with numerous customers from among the Fortune 500 list of companies, as well as NASA and leading universities. Graphene Laboratories Inc. has entered the global air filtration market with Breathe+, a line of medical grade HEPA air filtration products enhanced with advanced performance graphene material. 

G6 has identified new graphene-based applications to accelerate growth into the future. Accordingly, the Company has a valuable IP portfolio currently comprising five granted patents. The Company’s management team and employees have a deep understanding of graphene technology based on decades of aggregate academic and commercial experience. Graphene Laboratories Inc., a wholly owned subsidiary of G6 located in Ronkonkoma, New York, has established its premium research laboratory and scalable production facility is equipped with advanced analytical and material processing equipment. 

The Company’s e-commerce websites are listed below:

• Breathe: Medical grade HEPA air filtration enhanced with advanced performance graphene material, for more information, visitwww.breatheplus.tech 

• Conductive Epoxies: Adhesive materials distributed under the G6-EpoxyTM trade name and can be purchased at www.g6-epoxy.com 

• D Materials: Graphene Laboratories Inc. currently offers over 100 graphene and related products available atwww.graphene-supermarket.com  

Contact Details: 

Commercial Inquiries:

Telephone: (631) 405-5113

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.  

Investor Inquiries:

Nick Kuzyk, Investor Relations

Telephone:  1-(866)-324-4244

Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

ON BEHALF OF THE BOARD:  Daniel Stolyarov, President & Co-CEO 

For more information on G6 Materials Corp., please visit www.G6-Materials.com or its profile page on SEDAR at www.sedar.com.

Forward-Looking Information 

This news release contains forward-looking statements within the meaning of the applicable securities legislation that is based on expectations, estimates and projections as at the date of this news release. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. “Forward-looking information” in this news release includes but is not limited to information about the graphene-enhanced air purifier (including efficacy, potential commercialization and patent pending thereof); information about the potential for the Company’s long-term growth; the business goals and objectives of the Company, and other forward-looking information concerning the intentions, plans and future actions of the parties to the transactions described herein and the terms thereon. 

The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein. 

Risk factors that could cause actual results to differ materially include, but are not limited to, the risk that actual results in commercial applications of the graphene-enhanced air purifier may differ significantly from the Test Results; the Test Results may not be accepted by applicable regulatory agencies required to approve commercialization of the graphene-enhanced air purifier; the Company may not receive required approvals from regulatory agencies to commercialize the graphene-enhanced air purifier; the Company may not achieve further stages of commercialization of the graphene-enhanced air purifier as anticipated, or at all; the Company patent pending (US20210346831A1) may not be granted; the Company may not achieve anticipated commercial gains or profitability from the sale of Breathe+ Pro Advanced Antimicrobial Graphene Air Filtration System as currently anticipated, or at all; risks associated with adoption by industries of graphene-based products health and environmental factors affecting adoption of these technologies; the company may fail to obtain appropriate government approvals or accreditation related to the business’ operations and technological processes; the market conditions and demand for its product as well as the market prices of such products being developed by the company may change over time; reliance on key personnel; the potential for conflicts of interest among certain officers, directors or promoters with certain other projects; competition; dilution; and the volatility of our common share price and volume. 

The Company undertakes no obligation to revise or update any forward-looking information other than as required by law.